ERBB2 and triple-negative breast carcinoma: As a distinct subtype accounting for 10-20% of all breast cancers, triple-negative breast cancer (TNBC) lacks the expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2), resulting in an aggressive phenotype for which there is no targeted therapy [2].